ArticlesRandomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis
Introduction
Primary biliary cirrhosis (PBC) is a slowly progressive cholestatic liver disease that occurs with a male/female ratio of 1/9. The chronic cholestasis, due to immune-mediated destruction of small septal and interlobular bile ducts, can result in hepatic fibrosis, biliary cirrhosis, and eventually liver failure in many cases.1 Although liver transplantation offers very good results in patients with end-stage PBC, effective pharmacological treatment for patients with earlier stages of the disease is needed.
Currently, ursodeoxycholic acid (UDCA) is the only drug approved for the treatment of PBC and is widely prescribed by gastroenterologists and hepatologists.2 UDCA is believed to protect bile ducts against injury by hydrophobic bile acids and stimulate the hepatocellular elimination in bile of hydrophobic bile acids and other potential hepatotoxins.3 In 1987 Poupon and colleagues first reported benefit from UDCA;4 several randomised clinical trials have been reported since. Most showed a sustained improvement in biochemical factors, in particular serum bilirubin, which has been used as a good prognostic marker in PBC.5 Improved biochemical factors, however, have not been validated as surrogate markers of efficacy. Moreover, the effect of UDCA on survival and the clinical and histological progression of the disease is uncertain.
A combined analysis of three randomised trials,6 suggested that survival, free of transplantation, was significantly better in patients with PBC who received UDCA treatment for 4 years, than those who initially received placebo for 2 years followed by UDCA for the next 2 years. However, the extended follow-up of two other clinical trials7·8 with the same treatment design, as well as a randomised controlled trial with the longest follow-up,9 did not show a favourable effect of UDCA on the incidence of death or liver transplantation.
To clarify the real effect of UDCA on the progression of PBC, applying the methodology of evidence based medicine, we did a systematic review of the randomised clinical trials comparing UDCA with placebo, including the use of meta-analysis when this was applicable. We also did a critical assessment of the studies reporting the extended follow-up of the randomised trials, focusing on the switch-over phase from placebo to UDCA.
Section snippets
Study identification
We searched the Medline database and the Embase database from January, 1987, to July, 1998, to identify all English-language research included under the search textwords “primary biliary cirrhosis”, “ursodeoxycholic acid”, and “treatment”. We also did a full manual search of all review articles, of the retrieved original studies, and of all abstracts from the following major international meetings held between January, 1995, and October, 1998: American Digestive Disease Week; American
Descriptive and qualitative assessment
Searches of the Medline and Embase databases yielded 164 articles. Overall 11 randomised, placebo-controlled trials met the inclusion criteria.9, 14, 23 In one study22 three treatment groups were used on UDCA, colchicine, or placebo—only the data on UDCA and placebo were used for our analysis. We excluded only one study24 because it did not fulfil the inclusion criteria due to a follow-up interval of only 3 months.
The extended follow-up, reported for five trials, was evaluated separately,
Discussion
Although a meta-analysis does not replace the value of a large-scale, well-designed, randomised controlled trial to establish evidence for therapeutic efficacy, it is nonetheless useful when individual studies may be limited by small sample sizes and the paucity of endpoints. This is particularly the case in PBC, a disease with a very long natural history, which extends over decades.
Survival analysis is the “gold standard” for assessment of therapeutic efficacy in clinical trials of PBC.
References (39)
- et al.
Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis
Lancet
(1987) - et al.
Combined analysis of randomised controlled trials of ursodeoxycholic acid in primary biliary cirrhosis
Gastroenterology
(1997) - et al.
Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?
Hepatology
(1996) - et al.
Meta-analysis in clinical trials
Controlled Clin Trials
(1986) - et al.
Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial
Gastroenterology
(1989) - et al.
Ursodeoxycholic acid for symptomatic primary biliary cirrhosis: preliminary analysis of a double-blind multicenter trial
J Hepatol
(1993) - et al.
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Gastroenterology
(1994) - et al.
A randomised, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
Hepatology
(1995) - et al.
A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid
Gastroenterology
(1995) - et al.
Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis
Gastroenterology
(1996)
Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis
Mayo Clinic Proc
Primary biliary cirrhosis
N Engl J Med
Primary biliary cirrhosis: questions and promises
Ann Intern Med
Urosodeoxycholic acid in cholestatis: potential mechanisms of action and therapeutic applications
Hepatology
Serum bilirubin: a prognostic factor in primary biliary cirrhosis
Gut
Extended follow-up of patients in the US multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis
Gastroenterology
Quality, evolution, and clinical implications of randomised, controlled trials on the treatment of lung cancer: a lost opportunity for meta analysis
JAMA
Estimators of the Mantel-Haenszel variance consistent in both sparse data and large strata limiting models
Biometrics
Cited by (270)
Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid
2024, European Journal of Internal MedicineThe Inconvenient Truth of Primary Biliary Cholangitis/Autoimmune Hepatitis Overlap Syndrome
2022, Clinics in Liver DiseaseCitation Excerpt :UDCA is well established as the first-line treatment of PBC. Long-term clinical outcome studies have shown attenuation in fibrosis progression, a reduction in liver cancer risk, and prolonged liver transplant-free survival, particularly among individuals attaining biochemical response after 1 to 2 years of therapy.28–39 Second-line regimens vary but consist of licensed (OCA) and off-label bile acid therapies improve liver biochemistry and prolong transplant-free survival when combined with UDCA.40–54
Semisynthetic bile acids: a new therapeutic option for metabolic syndrome
2019, Pharmacological ResearchCitation Excerpt :Interestingly, an injection of deoxycholic acid (DCA) was the first FDA-approved drug for a cosmetic correction of submental fat [26]. Apart from approval of UDCA for primary biliary cirrhosis, now known as primary biliary cholangitis (PBC) [27], excellent in-depth reviews described its anti-inflammatory and antiapoptic function as well as the potential applications of its conjugated form - tauro-UDCA in T2DM, Parkinson’s disease, neuroinflammation, and spinal cord injury [14,28]. Subsequently, a great number of synthetic and semisynthetic bile acid analogues have been designed and assessed in preclinical and clinical settings.
Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis
2019, Journal of HepatologyNatural History of Primary Biliary Cholangitis in the Ursodeoxycholic Acid Era: Role of Scoring Systems
2018, Clinics in Liver DiseaseEASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis
2017, Journal of Hepatology